19-kD抗原与结核病小鼠模型中的保护性免疫
The 19-kD antigen and protective immunity in a murine model of tuberculosis.
作者信息
Yeremeev V V, Lyadova I V, Nikonenko B V, Apt A S, Abou-Zeid C, Inwald J, Young D B
机构信息
Laboratory for Immunogenetics, Central Institute for Tuberculosis, Moscow, Russia.
出版信息
Clin Exp Immunol. 2000 May;120(2):274-9. doi: 10.1046/j.1365-2249.2000.01212.x.
Abstract
The 19-kD antigen is a cell wall-associated lipoprotein present in Mycobacterium tuberculosis and in bacille Calmette-Guérin (BCG) vaccine strains. Expression of the 19-kD antigen as a recombinant protein in two saprophytic mycobacteria-M. vaccae and M. smegmatis-resulted in abrogation of their ability to confer protection against M. tuberculosis in a murine challenge model, and in their ability to prime a DTH response to cross-reactive mycobacterial antigens. Induction of an immune response to the 19-kD antigen by an alternative approach of DNA vaccination had no effect on subsequent M. tuberculosis challenge. These results are consistent with a model in which the presence of the 19-kD protein has a detrimental effect on the efficacy of vaccination with live mycobacteria. Targeted inactivation of genes encoding selected antigens represents a potential route towards development of improved vaccine candidates.
摘要
19-kD抗原是一种与细胞壁相关的脂蛋白，存在于结核分枝杆菌和卡介苗（BCG）疫苗株中。在两种腐生分枝杆菌——母牛分枝杆菌和耻垢分枝杆菌中，将19-kD抗原表达为重组蛋白，导致它们在小鼠攻击模型中丧失了针对结核分枝杆菌的保护能力，以及引发对交叉反应性分枝杆菌抗原的迟发型超敏反应（DTH）的能力。通过DNA疫苗接种这一替代方法诱导对19-kD抗原的免疫反应，对随后的结核分枝杆菌攻击没有影响。这些结果与一个模型相符，即19-kD蛋白的存在对活分枝杆菌疫苗接种的效果有不利影响。对编码选定抗原的基因进行靶向失活，是开发改良候选疫苗的一条潜在途径。
相似文献
1
The 19-kD antigen and protective immunity in a murine model of tuberculosis.
Clin Exp Immunol. 2000 May;120(2):274-9. doi: 10.1046/j.1365-2249.2000.01212.x.
2
Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting.
Int J Immunogenet. 2012 Apr;39(2):183-90. doi: 10.1111/j.1744-313X.2011.01066.x. Epub 2011 Dec 8.
3
Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice.
Scand J Immunol. 2010 Oct;72(4):349-57. doi: 10.1111/j.1365-3083.2010.02448.x.
4
Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.
Clin Dev Immunol. 2011;2011:617892. doi: 10.1155/2011/617892. Epub 2011 Feb 27.
5
Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.
Immunology. 2014 Oct;143(2):277-86. doi: 10.1111/imm.12308.
6
Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
J Infect Dis. 2008 May 1;197(9):1263-74. doi: 10.1086/586902.
7
A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice.
Med Microbiol Immunol. 2011 Aug;200(3):165-75. doi: 10.1007/s00430-011-0188-z. Epub 2011 Feb 22.
8
Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.
Infect Immun. 2010 Dec;78(12):5202-13. doi: 10.1128/IAI.00267-10. Epub 2010 Oct 4.
9
Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis.
Infect Immun. 2004 Nov;72(11):6471-9. doi: 10.1128/IAI.72.11.6471-6479.2004.
10
Immune responses and protective efficacy induced by 85B antigen and early secreted antigenic target-6 kDa antigen fusion protein secreted by recombinant bacille Calmette-Guérin.
Acta Biochim Biophys Sin (Shanghai). 2007 Apr;39(4):290-6. doi: 10.1111/j.1745-7270.2007.00281.x.
引用本文的文献
1
Stopping Tuberculosis at the Gate: The Role of Adhesins in Infection and Intervention.
Vaccines (Basel). 2025 Jun 24;13(7):676. doi: 10.3390/vaccines13070676.
2
DNA Subunit Vaccine and Recombinant BCG Based on Mycobacterial Lipoprotein LprO Enhance Anti-Tuberculosis Protection in the Lungs of Mice.
Vaccines (Basel). 2025 Apr 11;13(4):400. doi: 10.3390/vaccines13040400.
3
In silico design of multi-epitope adhesin protein vaccines.
Heliyon. 2024 Sep 7;10(18):e37536. doi: 10.1016/j.heliyon.2024.e37536. eCollection 2024 Sep 30.
4
Prediction of Epitopes in Virulence Proteins of for Vaccine Designing.
Curr Genomics. 2021 Dec 31;22(7):512-525. doi: 10.2174/1389202922666211129113917.
5
Adhesion molecules facilitate host-pathogen interaction & mediate pathogenesis.
Indian J Med Res. 2019 Jul;150(1):23-32. doi: 10.4103/ijmr.IJMR_2055_16.
6
Scrutiny of Mycobacterium tuberculosis 19 kDa antigen proteoforms provides new insights in the lipoglycoprotein biogenesis paradigm.
Sci Rep. 2017 Mar 8;7:43682. doi: 10.1038/srep43682.
7
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.
Nat Med. 2011 Sep 4;17(10):1261-8. doi: 10.1038/nm.2420.
8
Impact of toll-like receptor 2 deficiency on immune responses to mycobacterial antigens.
Infect Immun. 2011 Nov;79(11):4649-56. doi: 10.1128/IAI.05724-11. Epub 2011 Aug 15.
9
Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens.
Clin Vaccine Immunol. 2011 Jun;18(6):907-13. doi: 10.1128/CVI.00015-11. Epub 2011 Apr 6.
10
Modulation of cell death by M. tuberculosis as a strategy for pathogen survival.
Clin Dev Immunol. 2011;2011:678570. doi: 10.1155/2011/678570. Epub 2011 Jan 4.
本文引用的文献
1
An ex vivo study of T lymphocytes recovered from the lungs of I/St mice infected with and susceptible to Mycobacterium tuberculosis.
Infect Immun. 1998 Oct;66(10):4981-8. doi: 10.1128/IAI.66.10.4981-4988.1998.
2
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.
Nature. 1998 Jun 11;393(6685):537-44. doi: 10.1038/31159.
3
Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from Mycobacterium tuberculosis. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice.
Vaccine. 1998 Apr;16(7):692-7. doi: 10.1016/s0264-410x(97)00253-3.
4
Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection.
Infect Immun. 1998 Apr;66(4):1527-33. doi: 10.1128/IAI.66.4.1527-1533.1998.
5
Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection.
Immunology. 1997 Sep;92(1):6-9. doi: 10.1046/j.1365-2567.1997.00358.x.
6
Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection.
J Immunol. 1997 Jun 15;158(12):5921-6.
7
Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae.
Infect Immun. 1997 May;65(5):1856-62. doi: 10.1128/iai.65.5.1856-1862.1997.
8
9
The pathogenesis of tuberculosis.
Annu Rev Microbiol. 1996;50:259-84. doi: 10.1146/annurev.micro.50.1.259.
10
Immunogenicity and protective efficacy of a tuberculosis DNA vaccine.
Nat Med. 1996 Aug;2(8):893-8. doi: 10.1038/nm0896-893.
Zotero 插件